Avecho Biotechnology Limited (AVE.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.014 (+0.00%) as of
Key statistics
- Market cap
- 54.09M
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0055 – 0.0270
- Beta
- 1.27
- Revenue (TTM)
- 737.29k
- Profit margin
- 0.00%
- Volume
- 16.40M
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Clayton, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.